Key facts
- This page summarizes David V Smith's Form 4 filing for IO Biotech, Inc. (IOBT).
- 1 reported transaction and 1 derivative row are listed below.
- Filing timestamp: 03 Mar 2022, 15:30.
David V Smith - 01 Mar 2022 Form 4 Insider Report for IO Biotech, Inc. (IOBT)
- Role
- Director
- Signature
- /s/ Brian Burkavage, Attorney-in-Fact for David V. Smith
- Issuer symbol
- IOBT
- Transactions as of
- 01 Mar 2022
- Net transaction value
- $0
- Form type
- 4
- Filing time
- 03 Mar 2022, 15:30:24 UTC
- Previous filing
- 14 Jan 2022
- Next filing
- 31 May 2022
- SEC filing
- View on sec.gov
Reporting owner
Issuer context
Transaction snapshot
SEC evidence
Key filing fact
David V Smith filed Form 4 for IO Biotech, Inc. (IOBT) on 03 Mar 2022.
Change
- Previous filing in this sequence was filed on 14 Jan 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
See Original Filing
Ownership activity is grounded in SEC Form 4 disclosures.
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
IOBT
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +28,019
- Change %
- Price
- $0.000000
- Shares after
- 28,019
- Date
- 01 Mar 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 28,019
- Exercise price
- $6.89
- Footnotes
- F1
* indicates a reported price that failed the local validity check.
Explanation of Responses:
| Id | Content |
|---|---|
| F1 | These options vest monthly over three years from the vesting commencement date of March 1, 2022, subject to the reporting person's continued service through the applicable vesting date, and subject to 100% acceleration upon a change of control. |